Skip to main content
Figure 2 | BMC Medical Genomics

Figure 2

From: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Figure 2

RAS signature versus drug sensitivity or pathway activation. RAS signature score (Y-axis) versus cell sensitivity to a MEK inhibition (X-axis) across a panel of (A) lung or (B) breast cell lines. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines circled in bold in (A) have a KRAS mutation but have low signature scores and are resistant to MEK inhibition. (C) RAS signature score (Y-axis) versus cell sensitivity to an AKT inhibitor (X-axis) across a panel of breast cancer cell lines. Lower numbers on the X-axis indicate increasing sensitivity. (D) phospho-MEK (Y-axis) versus RAS signature score (X-axis) across a panel of breast cancer cell lines. In all cases, the RAS signature score was calculated relative to the mean of all cell lines in the respective experiment. R = Pearson correlation coefficient, p = the corresponding P-value.

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us